SCHEMBL25352910

SCHEMBL25352910

CN(C)C(C)(C)C(=O)Nc1cccc(-c2cn(Cc3ccc(-c4nnc(C(F)F)o4)cc3)nn2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 9/20 0.49
▸ KDR P35968 3/20 0.47
▸ TEK Q02763 2/20 0.47
▸ HDAC3 O15379 4/20 0.47
▸ HDAC1 Q13547 4/20 0.47
▸ HDAC2 Q92769 3/20 0.47
▸ HDAC10 Q969S8 3/20 0.47
▸ HDAC8 Q9BY41 3/20 0.47
▸ UCHL5 Q9Y5K5 1/20 0.44
▸ AKT1 P31749 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ SIRT2 Q8IXJ6 1/20 0.42
▸ HDAC4 P56524 1/20 0.41
▸ HDAC7 Q8WUI4 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC9 Q9UKV0 1/20 0.41
▸ HDAC5 Q9UQL6 1/20 0.41
▸ SNCA P37840 1/20 0.39
▸ AURKB Q96GD4 2/20 0.39
▸ STK17A Q9UEE5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30409092 0.93 KDM4E (0.53) HDAC6KDRTEKHDAC3HDAC1
SCHEMBL24215752 0.93 KDM4E (0.53) HDAC6KDRTEKHDAC3HDAC1
SCHEMBL30409499 0.92 HDAC6 (0.50) HDAC6KDRTEKHDAC3HDAC1
SCHEMBL24215759 0.92 HDAC6 (0.50) HDAC6KDRTEKHDAC3HDAC1
SCHEMBL25993048 0.90 KDM4E (0.42) HDAC6KDRTEKHDAC3HDAC1
SCHEMBL25350716 0.90 HDAC6 (0.47) HDAC6KDRTEKHDAC3HDAC1
SCHEMBL30425502 0.88 UCHL5 (0.56) HDAC6KDRTEKHDAC3HDAC1
SCHEMBL25207943 0.88 UCHL5 (0.56) HDAC6KDRTEKHDAC3HDAC1
SCHEMBL25350185 0.88 HDAC6 (0.52) HDAC6KDRTEKHDAC3HDAC1
SCHEMBL25350756 0.87 HDAC6 (0.53) HDAC6KDRTEKHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC3 HDAC6 1/4885KDR 4706/4885TEK 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback